CatSci Ltd is pleased to share that we will be attending the CPHI Event in Frankfurt, Germany on 1 – 3 November 2022. This is one of the biggest international pharmaceutical industry events, and we are delighted to be networking with the community.
This 3-day in-person event will be attended by:
• Jenn Clark, our Head of Customer Acquisition
• Dr Jas Douville, our Head of Business Development in North America
• Dr João Madeira, our Head of Business Development in Europe
• Dr Jenny Wallis, our Head of Business Development in UK and Japan
• Dr Sofia C. Papadouli, our Senior Marketing and Communications Manager
The team are looking forward to discussing CatSci’s capabilities and how we can de-risk your journey from molecule to medicine to expedite the delivery of life-changing therapeutics.
As we continue our ambitious expansion plans following our significant investment from Keensight, we are increasing our capabilities to meet our customers’ ever-evolving needs. We continue to develop our chemistry, manufacturing and controls (CMC) capability and capacity to become an end-to-end partner for innovation in the non-clinical development of medicines.
We see ourselves as an extension of our customers’ capabilities and take the time to understand external project objectives and provide perfect-for-purpose solutions through a unique consultative approach, refined workflows and technical expertise. We leverage our highly qualified technical staff and state-of-the-art facilities to empower our customers to create affordable, best-in-class small molecule therapeutics in a safer, greener and more cost-effective way.
Arrange a meeting with CatSci now to find out how we can address your dynamic portfolio challenges and deliver your pharmaceutical pipeline without surprises or delays.
Book a meeting with us now by contacting us here.
